Docetaxel loaded immunonanoparticles delivery in EGFR overexpressed breast carcinoma cells

Yewale, Chetan; Baradia, Dipesh; Patil, Sushilkumar; Bhatt, Priyanka; Amrutiya, Jitendra; Gandhi, Ravi; Kore, Girish; Misra, Ambikanandan

doi:10.1016/j.jddst.2018.03.027

Cited by 39 publications

(13 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The parameters for characterizing nanomicelles included a 90 degree measuring angle along with 25 • C temperature for each sample. Each cuvet consisted of 900 µL of filtered distilled water and 100 µL of the formulation [28]. The Zetasizer reported characterization data in triplicates, along with an average polydispersity index (PDI), which measures the biomolecular distribution of nanomicelles within a solution.…”

Section: Particle Size and Zeta Potentialmentioning

confidence: 99%

Sunitinib-Loaded MPEG-PCL Micelles for the Treatment of Age-Related Macular Degeneration

et al. 2020

Self Cite

View full text Add to dashboard Cite

Age-related macular degeneration (AMD) will be responsible for the vision impairment of more than five million late-aged adults in the next 30 years. Current treatment includes frequent intravitreal injections of anti-vascular endothelial growth factor (VEGF) agents. However, there are methods of drug delivery that can decrease the frequency of intravitreal injections by sustaining drug release. MPEG-PCL ((methoxypoly(ethylene glycol) poly(caprolactone)) has been reported as biocompatible and biodegradable. Polymeric micelles of MPEG-PCL can be useful in efficiently delivering anti-VEGF drugs such as sunitinib to the posterior segment of the eye. In this study, the novel micellar formulation exhibited an average dynamic light scattering (DLS) particle size of 134.2 ± 2.3 nm with a zeta potential of −0.159 ± 0.07 mV. TEM imaging further confirmed the nanoscopic size of the micelles. A sunitinib malate (SM)-MPEG-PCL formulation exhibited a sustained release profile for up to seven days with an overall release percentage of 95.56 ± 2.7%. In addition to their miniscule size, the SM-MPEG-PCL formulation showed minimal cytotoxicity onto the ARPE-19 human retinal pigment epithelial cell line, reporting a percent viability of more than 88% for all concentrations tested at time intervals of 24 h. The SM-MPEG-PCL micelles also exhibited exceptional performance during an anti-VEGF ELISA that decreased the overall VEGF protein expression in the cells across a 24–72 h period. Furthermore, it can be concluded that this type of polymeric vehicle is a promising solution to symptoms caused by AMD and improving the management of those suffering from AMD.

show abstract

Section: Particle Size and Zeta Potentialmentioning

confidence: 99%

Sunitinib-Loaded MPEG-PCL Micelles for the Treatment of Age-Related Macular Degeneration

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…The Trastuzumab is a monoclonal antibody is approved by the FDA in 1998 to act against HER-2. The HER-2 positive tumor can be cured by the Targeted poly NPs with the model toxin 63 . In breast cancer, quantum-dot loaded chitosan NPs and cross-linked human serum albumin NPs are provide effective treatment with HER -2 targeting.…”

Section: Targeting To Breast Cancermentioning

confidence: 99%

Active targeting of nanoparticles: An innovative technology for drug delivery in cancer therapeutics

Jani

Krupa

2019

J. Drug Delivery Ther.

View full text Add to dashboard Cite

In nanomedicines, currently a wide array of reported nanoparticle systems is being explored by targeting schemes which suggests great potential of targeted delivery to revolutionize cancer therapeutics. This review gives insight into recent challenges in modification of nanoparticle systems for enhanced cancer therapy acknowledged by researchers to date and also outlines different major targeting strategies of nanoparticle systems that have been utilized for the delivery of therapeutics or imaging agents, targeting ligand and cross-linking agent to cancer which was divided into three sections: 1) Angiogenesis associated targeting, 2) Uncontrolled cell proliferation targeting and 3) Tumor cell targeting. Keywords: nanoparticles, tumor cells, active targeting, targeting strategies, targeting ligands

show abstract

“…One way to obtain this ideal drug delivery system is through the entrapment of drugs within polymeric nanoparticles (NPs) (1-1,000 nm) or microparticles (MPs) (1-1,000 mm). [4][5][6] Micro-/ nano-based systems possess the unique ability to be designed to meet specific needs based on their intended application because their structures are made up of atoms/molecules with various sizes and morphologies. These structures may be applied to the field of pharmaceutics by encapsulating active pharmaceutical agents to improve efficacy, sustainability, distribution, biocompatibility, and toxicity.…”

Section: Nanoparticles Versus Microparticlesmentioning

confidence: 99%

Micro/Nanoparticle Delivery Systems for Ocular Diseases

Halasz

Kelly

Iqbal

et al. 2019

ASSAY and Drug Development Technologies

View full text Add to dashboard Cite

Micro-(MPs) and nanoparticles (NPs) have been recently studied for their application in ophthalmic drug delivery. These drug delivery systems are able to circumvent the ocular barriers that currently limit the efficacy of conventional treatments, as well as provide a more sustained release of drug, reducing the frequency of administration and increasing patient compliance. This review summarizes the recent trends in ophthalmic research from conventional treatment to the utilization of MPs and NPs as drug carriers.

show abstract

Docetaxel loaded immunonanoparticles delivery in EGFR overexpressed breast carcinoma cells

Cited by 39 publications

References 35 publications

Sunitinib-Loaded MPEG-PCL Micelles for the Treatment of Age-Related Macular Degeneration

Sunitinib-Loaded MPEG-PCL Micelles for the Treatment of Age-Related Macular Degeneration

Active targeting of nanoparticles: An innovative technology for drug delivery in cancer therapeutics

Micro/Nanoparticle Delivery Systems for Ocular Diseases

Contact Info

Product

Resources

About